Archive for February, 2021

$CLXPF How Psychedelics Are Helping Advance Modern Technology

In the 1950s, Oscar Janiger, a psychiatrist interested in LSD’s effect on creativity, dosed more than 950 individuals with the drug in his LA home. He carefully wrote down each individual’s experience and concluded at the end of his experiment that LSD could affect individuals who were already creative but could not make noncreative individuals more creative.

He recognized that while LSD couldn’t inspire an individual who wasn’t creative to suddenly begin writing poetry or painting, it did provide creative individuals insights into their craft’s nature.

Another researcher who was immensely interested in LSD, a chemist by the name of Albert Hoffman, spent years trying to learn more about this psychedelic substance. His discovery of LSD is what drove the entire neuroscience field to conduct numerous studies on the drug. The thousands of studies that were carried out in the ’50s and early ’60s drove science in a new direction.

Later, in 1973, American psychologist Timothy Leary forecasted that one day the world would be connected by a new electronic nervous system. He believed that psychedelics could help the advancement of technology. Cyberpunks later considered his prophetic message to be an internet-inspired vision.

This ushered in Silicon Valley, which was looking to build a future that was digitally connected. Steve Jobs, one of the founders of Apple, attributes LSD trips to being some of the most important things in his life. He admitted to having consumed sugar cubes that were laced with LSD a dozen or so times between 1972–1974. He later co-founded Apple with Steve Wozniak in 1976.

By now you may be asking yourself, “Did the computer revolution occur because of psychedelics?”

While many see Leary as the hippie-era cosmic clown, he did verify Janiger’s discovery that if individuals were critical thinkers, psychedelics could help them become more creative. The term “psychedelic,” which was coined in 1956 by psychiatrist Humphry Osmond, refers to “mind manifesting.” This would explain Leary’s knowledge on the human imagination having limitless potential for manifesting any idea, no matter how unconventional it was.

Various technological applications produced in Silicon Valley are a fruit of imagination, productivity-induced microdosing or both. One such application is Neuralink, a brain-machine interface that connects software with an individual’s thoughts. Even though it’s still in development, many are hopeful that this breakthrough invention could revolutionize various fields.

Another application has been developed through Cybin Inc. (NEO: CYBN) (OTC: CLXPF)’s partnership with Kernel, a firm of neuroscience tech makers. Their invention, an fMRI scanner, observes the activity of individuals’ brains when they are tripping. The partners hope that this consumer-grade device will become a household appliance by the 2030s.

There is still so much yet to be discovered with regard to psychedelics and how they influence technology. However, their promising potential indicates that great things lie ahead.

NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (OTC: CLXPF) are available in the company’s newsroom at https://ibn.fm/CYBN

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Monday, February 22nd, 2021 Uncategorized Comments Off on $CLXPF How Psychedelics Are Helping Advance Modern Technology

$CNSP Eyes Transformation as Berubicin Becomes Subject of Active Clinical Trials

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system. The company’s pipeline includes Berubicin for the treatment of patients with glioblastoma multiforme (“GBM”), an aggressive form of brain cancer that is incurable. CNS is currently focused on the development and clinical trials of Berubicin for GBM, as well as the potential of addressing other central nervous system malignancies. “The company will transform within the next several months as Berubicin becomes the subject of up to three active clinical trials, which include our randomized, controlled Phase II trial in the U.S., and two trials planned by our sublicensee WPD in Poland,” CNS Pharmaceuticals CEO John Climaco said during a recent virtual presentation discussing the FDA IND approval and future company plans.

To view the full article, visit: https://ibn.fm/qhy8l

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at http://ibn.fm/CNSP

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Monday, February 22nd, 2021 Uncategorized Comments Off on $CNSP Eyes Transformation as Berubicin Becomes Subject of Active Clinical Trials

$MOTNF PowerTap to Commercialize 3rd Generation Blue Hydrogen System into New Verticals

Clean Power (CSE: MOVE) (OTC: MOTNF) (FWB: 2K6A) today provided additional information about how the onsite hydrogen production and dispensing technology being developed by PowerTap Hydrogen Fueling Corp., an investee company of Clean Power, will be used in other commercial markers. According to the update, PowerTap has commenced plans to commercialize its third generation units into new verticals such as commercial buses and trains, and has initiated partnership discussions with various cities and states/provinces. Subject to the progression of PowerTap’s plan to expand its product offering, its third generation onsite hydrogen production module will be made available to provide blue hydrogen for trains and buses, in addition to hydrogen fuel cell cars and trucks. A prime example of this growing market is the Coradia iLint, a hydrogen train built by Alstom in Salzgitter, Germany and currently being deployed in Europe*. The Corada iLint is the world’s first passenger train powered by on-board hydrogen fuel cells producing electrical power for traction. This relatively low-noise, zero-emission train only exhausts steam and condensed water as atmospheric outputs. “PowerTap continues to have discussions with various commercial opportunities in various verticals and will continue to update shareholders in the coming weeks and months,” said PowerTap CEO Raghu KIlambi.

To view the full press release, visit http://ibn.fm/gotUt

About Clean Power Capital Corp.

Clean Power specializes in investing into private and public companies opportunistically that may be engaged in a variety of industries, with a current focus in the health and renewable energy industries. In particular, the mandate is focused on high return investment opportunities, the ability to achieve a reasonable rate of capital appreciation and to seek liquidity in the company’s investments. A copy of Clean Power’s amended and restated investment policy may be found under the company’s profile at www.SEDAR.com. For more information, visit the company’s website at www.CleanPower.capital.

*https://www.alstom.com/solutions/rolling-stock/coradia-ilint-worlds-1st-hydrogen-powered-train

NOTE TO INVESTORS: The latest news and updates relating to MOTNF are available in the company’s newsroom at http://ibn.fm/MOTNF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Monday, February 22nd, 2021 Uncategorized Comments Off on $MOTNF PowerTap to Commercialize 3rd Generation Blue Hydrogen System into New Verticals

$MOTNF Announces USA Hydrogen Station Distribution Model

  • PowerTap Hydrogen Fueling has signed a definitive agreement with the Andretti Group to create an optimized network by leveraging the latter’s operational expertise and global reach
  • PowerTap plans to have 500 operational hydrogen filling stations deployed across the country by the end of 2025
  • The existing business model’s deployment of hydrogen stations expedites rollout due to the existing fuel operations on each site
  • The hydrogen fuel cell vehicle market worldwide was valued at $651.9 million in 2018 and is expected to grow to over $42 billion by 2026

Stemming from the announcement made by Clean Power Capital (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF) on January 26, 2021, about the Definitive Agreement between investee PowerTap Hydrogen Fueling and the Andretti Group for the production and deployment of hydrogen fuel units across California, more details have been released regarding the agreed-on business model, as well as the agreement’s benefits for the parties involved (https://ibn.fm/WYoYt).

PowerTap is working to build and expand its hydrogen fueling station network, initially across North America, starting the second half of 2021. The platform is believed to be more cost-effective and expandable than other hydrogen filling station’s models. The significant advantage over these companies comes from PowerTap’s smaller physical footprint and capacity to produce hydrogen on-site. Other companies purchase hydrogen at high prices and store it.

To be eligible to host a hydrogen fueling station, a site needs to meet a series of requirements, including: to have an existing fuels retailer, a usable area of at least 1000 square feet, as well as access to utilities, including natural gas, electricity, and water.

The key points for the business model are:

  • The retailer provides the land, with no leasing expenses required of PowerTap
  • PowerTap, at their own expense, will install and maintain the modular hydrogen production and dispensing unit. These expenses also include branding costs and utilities.
  • The retailer will market hydrogen fuel and generate profit the same way traditional fuel sales are conducted.

Under the agreement, participating retails have a number of advantages, including:

  • A high-yield opportunity to create revenue out of the land that is not being used to full potential
  • Retailers are eligible to receive a portion of the carbon credit revenue
  • Minimal operating costs and high earnings as an additional means of profit
  • New clientele group, generating additional purchases of other products or services
  • The on-site production allows a competitive price (go-to-market) versus the delivered supply price

The advantages for PowerTap include:

  • No land purchase or leasing expenses
  • Co-development that provides access to prime and higher trafficked real estate
  • A faster entitlement process due to the existing fuel operation
  • Ability to leverage the Andretti Group’s established operations expertise and geographical reach for a more optimized network
  • Ability to expedite rollout, with the deployment of over 500 PowerTap modular hydrogen production and dispensing units by the end of 2025

The PowerTap technology has already been deployed across multiple hydrogen fueling stations in both public and private enterprises. These can be found in California, Maryland, Massachusetts, and Texas. By the end of 2025, PowerTap plans to deploy over 500 stations at existing truck stops and gas stations across the country. At present, there are under 100 active hydrogen fueling stations operational and available to consumers.

The hydrogen fueling network plan enables PowerTap and by extension Clean Power Capital to access a fast-growing market rife with expansion opportunities. According to Allied Market Research, the global hydrogen fuel cell vehicle market, valued at $651.9 million in 2018, is expected to grow at a CAGR of 66.9% to 2026, reaching an estimated value of $42,038.9 million (https://ibn.fm/Rg9Te). The key factor influencing the push for hydrogen fuel vehicles is the surge in environmental concerns over traditional fossil fuels. Hydrogen fuel does not generate greenhouse gas (“GHG”) emissions during operation like diesel and gasoline-powered vehicles.

The United States is already engaging in the hydrogen economy and currently leads in the number of hydrogen cell vehicles globally. The government is investing hundreds of millions of dollars per year in the hydrogen fuel industry, helping potentially create approximately 3.4 million jobs within the next three decades (https://ibn.fm/qF0M4).

For more information, visit the company’s website at www.CleanPower.Capital.

NOTE TO INVESTORS: The latest news and updates relating to MOTNF are available in the company’s newsroom at https://ibn.fm/MOTNF

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com

Green Car Stocks is part of the InvestorBrandNetwork.

Monday, February 22nd, 2021 Uncategorized Comments Off on $MOTNF Announces USA Hydrogen Station Distribution Model

$BRSF E-Tattoo Will Be ‘Next Wave of Innovation for Neurology’

Brain Scientific (OTCQB: BRSF) is a commercial-stage health care company focused on developing innovative and proprietary medical devices and software. As scientists work to understand what causes Parkinson’s, Alzheimer’s, dementia and other neurological issues, BRSF is making inroads in helping identify root neurological problems. The company has unveiled a new initiative to develop an innovative e-tattoo device for the brain diagnostics market. The Brain E-Tattoo’s graphene-based electrodes are designed for connection to the micro EEG clipped behind the ear, which processes the signals from the sensors and wirelessly transfers data to a cloud application. The solution enables each patient’s data to be secured in the cloud where Brain Scientific’s artificial intelligence performs continuous analysis, providing 24/7 uninterrupted seizure monitoring. Dating back to 1929, drastic advances to the EEG have only been seen in the last few decades. “COVID-19 put a spotlight on the outdated and inefficient EEG testing protocols,” said Boris Goldstein, BRSF co-founder and executive. “Disposable technology made a significant impact to ensure brain scans could occur safely during the pandemic. Now, brain e-tattoos implanted in the forehead will be the next wave of innovation for neurology. The advancement will allow for long-term monitoring capabilities and uninterrupted data collection from patients with neurological conditions. Clinicians will be able to identify brain wave activity beyond the clinical setting with no impact to the patient’s daily life. While we aren’t yet ready as a society to cyborg our way past neurological issues, we are on the cusp of better understanding and diagnosing them. Thanks to cutting-edge technology like BRSF’s E-Tattoo, answers are right around the corner.”

To view the full article, visit: https://ibn.fm/O1DOu

About Brain Scientific Inc.

Brain Scientific is a commercial-stage health-care company with two FDA-cleared products, providing next-gen solutions to the neurology market. The company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. To learn more about the company’s corporate strategy, devices or for investor relations, visit www.BrainScientific.com.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at http://ibn.fm/BRSF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Monday, February 22nd, 2021 Uncategorized Comments Off on $BRSF E-Tattoo Will Be ‘Next Wave of Innovation for Neurology’

$AZRX Coronavirus Pandemic Exposes Biomedical Waste Disposal Challenge in India

The coronavirus pandemic has impacted various sectors, including the environment, economic, social and health industries. While the vaccine has given people hope, the absence of a strategy that will be used to dispose of any coronavirus-related biomedical waste remains a threat.

The Central Pollution Control Board in India recently released data showing that between June and December 20202, the coronavirus-related biomedical waste that was generated measured an estimated 33,000 tons. Earlier in July, the board presented a report to the National Green Tribunal indicating that India generated 101 MT of coronavirus-related biomedical waste daily and an additional 609 metric tons through other means.

In the country, cities that had experienced high numbers of coronavirus cases are now dealing with the problem of contaminated/used PPEs, including shoe covers, gloves and masks being dumped out in the open or with household waste. This is despite the fact that PPE kits had been restricted for use by medical personnel only. By disposing personal protective equipment kits with regular garbage, the persons living in those areas have posed a great risk to the ecosystem.

While coronavirus care centers and hospitals have put in place measures for the sorting of waste, the unscientific disposal of coronavirus biomedical waste by private contractors and corporations is alarming. There is no method to check whether waste has been stored properly before it is incinerated, and neither is there a way to track trucks that carry biomedical waste.

The government of India and the World Health Organization (“WHO”) offered guidelines on how to discard coronavirus-related biomedical waste, which include protection for sanitation workers and proper separation of waste. However, the pandemic has affected the garbage disposal chain, which has disrupted temporary storage, transport, sorting and waste management of biomedical waste. Additionally, proper sorting of wet and dry waste is still not adhered to, which is also affecting the disposal chain.

Furthermore, sanitation workers are rarely provided with adequate PPE kits, water and soap, which are basic necessities during this pandemic. It doesn’t help that these workers are usually underpaid by municipal corporations with safety guidelines often not enforced. This means that proper balances and checks are rarely conducted to ensure the workers’ safety.

In addition to this, biomedical waste has also impacted the animals, soil, water and air. As India doesn’t have proper water treatment plants for sewage, most sewage water, which contains feces and fluids of coronavirus patients, flows into bodies of water bodies such as the sea and rivers. This will contaminate the water bodies and, with researchers still unsure of the long- and short-term effects of this pollution, many remain concerned.

To what extent is this biomedical waste disposal problem playing out in different countries around the globe?

Away from the issues of biomedical waste disposal, lots of companies are doing a lot to find treatments for some of the most challenging conditions. An example is AzurRx BioPharma Inc. (NASDAQ: AZRX), which has completed two Phase 2 clinical trials on a drug candidate intended to treat EPI (exocrine pancreatic insufficiency) among chronic pancreatitis sufferers and those with cystic fibrosis.

NOTE TO INVESTORS: The latest news and updates relating to AzurRx BioPharma Inc. (NASDAQ: AZRX) are available in the company’s newsroom at https://ibn.fm/AZRX

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Monday, February 22nd, 2021 Uncategorized Comments Off on $AZRX Coronavirus Pandemic Exposes Biomedical Waste Disposal Challenge in India

$AMST Founder, CEO Slated to Present at Upcoming Diamond Equity Research Emerging Growth Conference

Amesite(NASDAQ: AMST) founder and CEO Dr. Ann Marie Sastry is scheduled to present at the Diamond Equity Research Emerging Growth Invitational. The one-day premier event will be held on Wednesday, Feb. 24, with Sastry’s presentation scheduled for 12:20 p.m. ET. During her presentation, Sastry will provide an overview of the Amesite story and discuss how the company’s award-winning, highly scalable artificial intelligence (“AI”) driven platform is impacting the way the world learns. A live audio webcast and archive of the conference presentation will be available using the registration link. AMST operates in a U.S. online learning market of $350 billion and is becoming recognized for its cloud-based online learning platform that is considered the most advanced in the industry. Amesite is a high-tech artificial intelligence software company offering a cloud-based platform and content creation services for business, university and K-12 learning and upskilling. “I look forward to sharing our story with the investment community,” said Amesite founder and CEO Ann Marie Sastry in the press release. “Online learning is the future of professional and student education and we are well-positioned to serve this large and growing global multi-trillion-dollar market, and deliver more engaging, effective and accessible learning experiences for all.”

To register for the conference, visit http://ibn.fm/70s3k

To view the full press release, visit http://ibn.fm/kAFsi

About Amesite Inc.

Amesite is a high-tech, artificial intelligence software company offering a cloud-based platform and content creation services for business, university and K-12 learning and upskilling. Amesite-offered courses and programs are branded to its customers. For more information about the company, please visit www.Amesite.com.

NOTE TO INVESTORS: The latest news and updates relating to AMST are available in the company’s newsroom at http://ibn.fm/AMST

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Monday, February 22nd, 2021 Uncategorized Comments Off on $AMST Founder, CEO Slated to Present at Upcoming Diamond Equity Research Emerging Growth Conference

$HWAL HW Vision to Advance Technological Footprint Through Strategic Agreement

Hollywall Entertainment (OTC: HWAL), an innovative telecommunication and broadcasting company, has begun the rollout of its new wholly owned subsidiary HW Vision. According to a recent update, the subsidiary will provide branded cellular equipment and services, streaming media content, live television and on-demand programming as part of Hollywall’s drive to become a major media and entertainment conglomerate. An article discussing this reads, “HWAL’s subsidiary HW Vision will be advancing its technological footprint via its entry into an agreement to acquire top United States telecommunications firm Omnipoint Technology Inc., a Massachusetts-based telecommunications company, to deliver the services — including content from Hollywall’s large entertainment library and educational programming catalogue — to residential homes and commercial businesses through its network across the Eastern and Southern United States.”

To view the full article, visit https://ibn.fm/nr5GV

About Hollywall Entertainment Inc.

Hollywall Entertainment is a telecommunications, technology, media, entertainment and broadcasting company that operates through its various subsidiaries including: Hollywall Development Company (“HWDC”), HW Vision and HW Latlong, and multiple divisions to include HW School of Communications, Hollywall Music, Hollywall TV, HW Productions, HW Networks, HWRadio, HWGOV and The Hollywall Foundation. HWAL continues to maximize rights to its music, film, television, home videos and software game libraries. Hollywall owns exclusive and nonexclusive rights to market, manufacture and distribute music master recordings performed by legends such as Ray Charles, Ella Fitzgerald, The Jackson 5, Frank Sinatra, Dolly Parton, Elvis Presley, Tony Bennett, The Bee Gees, Chicago, The Platters, George Gershwin, Marvin Gaye, James Brown, The Who, Janis Joplin, Rolling Stones, Nat King Cole, John Lee Hooker, Willie Nelson, Rod Stewart, Hall and Oates, James Taylor, Etta James, Aretha Franklin, and other multiple-platinum-selling acts. Learn more at www.Hollywall.co​m.

NOTE TO INVESTORS: The latest news and updates relating to HWAL are available in the company’s newsroom at http://ibn.fm/HWAL

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Monday, February 22nd, 2021 Uncategorized Comments Off on $HWAL HW Vision to Advance Technological Footprint Through Strategic Agreement

$XPHYF Announces Expedited Formation of Team to Launch Test System, Also Comments on Lawsuit Against German Subsidiary

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) announced that it has accelerated the creation of a commercial team formed to launch its point-of-care COVID-19 RT-PCR (“RT-PCR”) test system, called the COVID ID Lab. The lab was developed by XPhyto’s exclusive German diagnostics development partner, 3a-diagnostics GmbH (“3a”). It is anticipated that 3a will receive ISO 13485 medical device manufacturer approval by the end of February; European regulatory approval should be received by early March. The announcement noted that the market launch team consists of highly skilled clinical and pharmaceutical executives and service providers with the expertise and background to rapidly drive the commercialization of Covid-ID Lab. “We are extremely fortunate to now have a team with deep expertise in medical diagnostic product commercialization,” said XPhyto CEO and director Hugh Rogers in the press release. “The team has extensive experience from regulatory approval to international production and sales. As we near expected regulatory approval, XPhyto’s business is rapidly evolving from innovation to impact. We are working hard to put the Company in the best possible position to execute on our business strategy.” XPhyto also released a statement regarding a claim made against Vektor Pharma TF GMBH (“Vektor”), one of its German subsidiaries. The claim notes that “Vektor is subject to a declaratory action made by a former client and current competitor in relation to alleged breach of the terms of a development agreement between Vektor and the claimant. The claimant has estimated its alleged damages at 1 million Euros. Vektor and management of the corporation believe the claim is substantially without merit and intend to defend the claim vigorously. Vektor has filed a notice of defense in the respective German court. In the event that a court finds Vektor to be liable for damages, even in the amount estimated by the Claimant, such judgment is not expected to have a material adverse effect on the business or affairs of Vektor or the corporation. The corporation will provide further updates as the action progresses.”

For more information, visit https://ibn.fm/UV279 and  https://ibn.fm/qjVMJ

About XPhyto Therapeutics Corp.

XPhyto Therapeutics is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral-health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. XPhyto has research and development operations in North America and Europe, with an operational focus in Germany, and the company is currently focused on regulatory approval and commercialization of medical products for European markets. For more information about this company, please visit www.XPhyto.com

NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at http://ibn.fm/XPHYF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Monday, February 22nd, 2021 Uncategorized Comments Off on $XPHYF Announces Expedited Formation of Team to Launch Test System, Also Comments on Lawsuit Against German Subsidiary

$XPHYF Advances Rapid COVID Test System, Expands Psychedelic Medicine Programs

  • Life sciences industry accelerator XPhyto Therapeutics Corp. has developed a timeline for the approval and rollout of a rapid, portable COVID-19 test it expects to become available by April in Europe
  • XPhyto’s Covid-ID Lab system is designed to help industries economically devastated by the pandemic to form strategies based on quick and accurate testing, particularly the travel industry
  • The company intends to use its test tech partnership with Germany’s 3a-diagnostics GmbH to build additional bacteriological and viral testing products
  • A separate subsidiary based in Alberta is developing psychedelic medicine programs
  • The subsidiary recently announced it has added mescaline production to the program for potential use in treating addiction and depression

Canada-based bioscience accelerator XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) has completed all the preparatory actions necessary for it to apply for approval of its COVID-19 rapid and portable test system under European regulatory authorities, the company announced Feb. 16.

The quick-response point-of-care SARS-CoV-2 RT-PCR Test System known as “Covid-ID Lab” developed in partnership with Germany’s 3a-diagnostics GmbH is designed to provide robust and accurate COVID-19 testing for economically devastated market sectors, with particular emphasis on travel industries. The announcement is one of a pair of company developments to emerge this month, including the expansion of the holding company’s psychedelic medicine programs.

In regard to the COVID test, 3a expects to obtain approval as a medical device manufacturer under internationally agreed-on ISO 13485 quality standards by late February, followed by European regulatory approval of Covid-ID Lab as a commercial in vitro diagnostic device (CE-IVD) by early March, according to the company’s announcement (https://ibn.fm/89jKh).

The companies then plan for manufacturing to begin in Germany with an April target for Covid-ID Lab’s sales launch in Europe. XPhyto is building relationships with partners in other countries to further advance the system’s sales and distribution.

“Our goal was to create the fastest and most portable COVID-19 PCR test on the market,” XPhyto CEO and Director Hugh Rogers stated. “We are very pleased with the team’s swift development progress.”

The pandemic has had a calamitous effect on the tourism industry during the past year, especially for popular island destinations ranging from Hawaii to Australia and New Zealand. Domestically, Hawaii has experimented with resort “bubbles” and recently announced a test-dependent Health Pass agreement that will help travelers avoid a mandatory 10-day quarantine once they arrive on the islands (https://ibn.fm/yuQQd), while United Airlines became the first U.S. carrier to establish an in-airport testing partner and information service, according to a CBS News report (https://ibn.fm/Af5A6).

But the growing spread of COVID virus variants from the United Kingdom, South Africa and Brazil is creating new urgency about safeguarding international travel. India’s new air travel guidelines issued Feb. 18 are just the latest efforts to limit transmission of the worldwide health crisis, and experts believe varied restrictions will remain in place for a long time to come.

“Like 9/11 changed air security forever, we’re still taking our shoes off,” XpresCheck CEO Doug Satzman stated in the CBS News report. “COVID is going to change safety protocol in airports for a long time as well.”

The U.S. Centers for Disease Control and Prevention (“CDC”) has advised against such travel entirely, but has added testing recommendations for people who ignore its advice. In late January, the agency broadened international travel requirements, making negative COVID tests mandatory for passengers coming from any international location to the United States despite airline industry resistance (https://ibn.fm/rnoG3).

XPhyto’s rapid-response test system aims to give businesses and government authorities a powerful tool in their arsenals, and the COVID response is only the beginning. The company is also working with 3a to develop a portfolio of oral biosensor screening tests that detect bacterial and viral infectious diseases ranging from influenza A to group A strep, and is focusing on other potential pandemic biosensor tech efforts to combat the spread of the H1N1 (swine flu) and H5N1 (avian flu) viruses.

The company states it is planning to launch its first biosensor product commercially during the latter half of 2021.

Elsewhere, one of XPhyto’s holdings in Canada, XPhyto Laboratories Inc., has added mescaline production to its psychedelic medicine programs, according to a Feb. 3 announcement (https://ibn.fm/zyiEL).

Mescaline is listed as a Schedule I drug in the United States without legally recognized medicinal benefits and with a high risk of abuse, but the psychedelic substance occurs naturally in some types of cactus and has limited legal use in certain religious ceremonies registered by the Native American Church and in certain research efforts. However, its use is expanding internationally as a supplement to various types of meditation and psychedelic therapies, according to the company.

“Mescaline has been anecdotally recognized as a relatively safe psychedelic drug and has shown particular promise for the treatment of addiction and depression,” XPhyto’s news release states.

For more information, visit the company’s website at www.XPhyto.com.

NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Monday, February 22nd, 2021 Uncategorized Comments Off on $XPHYF Advances Rapid COVID Test System, Expands Psychedelic Medicine Programs

$WRAP Buffalo Police Department Deploy BolaWrap to Detain Woman During Mental Health Call

TEMPE, Ariz., Feb. 22, 2021  — Wrap Technologies, Inc. (the “Company” or “WRAP”) (Nasdaq: WRAP ), an innovator of modern policing solutions, reported the successful deployment of the BolaWrap by the Buffalo Police Department while responding to a mental health call of a woman in crisis on Friday.

In September of 2020, Buffalo Mayor Byron Brown and the Buffalo Police Department held a press conference to discuss and demonstrate BolaWrap for the public.

In October of 2020, Mayor Brown and Common Council President Darius Pridgen announced the launch of a BolaWrap pilot program as part of an innovative public safety initiative.

In January of 2021, CBS-affiliate WIVB reported that the pandemic had pushed back training sessions for the equipment, but that police officials had announced training for the BolaWrap would start in the next couple of weeks.

On Friday, less than one month after BolaWrap training began, Buffalo Police Department successfully deployed the BolaWrap on a women in mental crisis, enabling them to take her into custody and transport to a mental health facility without injury, as reported by WIVB and NBC-affiliate WGRZ .

According to WGRZ,

‘At around 2 p.m. Friday near Kenfield-Langfield, police received a call with concern about a woman who may have the potential to cause harm to herself or others and was underdressed in the snow. Police were concerned about hypothermia exposure for the woman.

Police say they spoke with the woman for an extended period of time, asking her to get in a police car and receive medical evaluation. The woman refused, which police say prompted them to deploy the Bolawrap.

The device allowed police to transport her to Erie County Medical Center for evaluation without anyone getting hurt, according to police.’

“Public safety includes solutions that can de-escalate encounters, and that’s exactly what the BolaWrap does,” said Tom Smith, President of WRAP. “BolaWrap doesn’t rely on pain compliance and is designed to de-escalate situations and provide needed support for persons in crisis. We are pleased to continue seeing successful field deployments of the BolaWrap, especially by the police department of New York’s second-largest city.”

In October of 2020, Smith participated in City & State’s 2020 Protecting New York Summit alongside NYC Public Advocate Jumaane Williams, NYC Councilmember Donovan Richard, and industry executives for a solutions-oriented discussion on reimagining public safety in New York. WRAP sees the Buffalo pilot program as an important element of public safety in New York.

About WRAP
WRAP Technologies, Inc. is an innovator of modern policing solutions. The Company’s BolaWrap 100 product is a patented, hand-held remote restraint device that discharges an eight-foot bola style Kevlar® tether to restrain an individual at a distance from 10 to 25 feet. Developed by award winning inventor Elwood Norris, the Company’s Chief Technology Officer, the small but powerful BolaWrap 100 assists law enforcement in safely and effectively deescalating encounters, especially those involving an individual in crisis. BolaWrap 100 has already been used to safely apprehend suspects without injury in a number of cities including Los Angeles, Sacramento, Fresno, Bell, Albuquerque, Minneapolis, West Palm Beach, Fort Worth, and Oak Ridge. For information on the Company, please visit www.wrap.com.

Follow WRAP here:

WRAP on Facebook: https://www.facebook.com/wraptechnologies/
WRAP on Twitter: https://twitter.com/wraptechinc
WRAP on LinkedIn: https://www.linkedin.com/company/wraptechnologies/

Trademark Information
BolaWrap and Wrap are trademarks of WRAP Technologies, Inc. All other trade names used herein are either trademarks or registered trademarks of the respective holders.

Cautionary Note on Forward-Looking Statements – Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to: statements regarding the Company’s overall business; total addressable market; and, expectations regarding future sales and expenses. Words such as “expect”, “anticipate”, “should”, “believe”, “target”, “project”, “goals”, “estimate”, “potential”, “predict”, “may”, “will”, “could”, “intend”, and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Moreover, forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company’s control. The Company’s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: the Company’s ability to successful implement training programs for the use of its products; the Company’s ability to manufacture and produce product for its customers; the Company’s ability to develop sales for its new product solution; the acceptance of existing and future products; the availability of funding to continue to finance operations; the complexity, expense and time associated with sales to law enforcement and government entities; the lengthy evaluation and sales cycle for the Company’s product solution; product defects; litigation risks from alleged product-related injuries; risks of government regulations; the business impact of health crises or outbreaks of disease, such as epidemics or pandemics; the ability to obtain export licenses for counties outside of the US; the ability to obtain patents and defend IP against competitors; the impact of competitive products and solutions; and the Company’s ability to maintain and enhance its brand, as well as other risk factors mentioned in the Company’s most recent annual report on Form 10-K, quarterly report on Form 10-Q, and other SEC filings. These forward-looking statements are made as of the date of this press release and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.

WRAP Contact:

Paul M. Manley
VP – Investor Relations
(612) 834-1804
pmanley@wrap.com

Monday, February 22nd, 2021 Uncategorized Comments Off on $WRAP Buffalo Police Department Deploy BolaWrap to Detain Woman During Mental Health Call

$VTGN Committed to Developing New Generation Alternatives to Current Standard of Care for Anxiety Disorders

  • American Psychiatric Association poll reveals 62% of respondents have anxiety about COVID-19
  • Recent FDA Drug Safety Communication requires updated Boxed Warning for benzodiazepines commonly used to treat anxiety disorders
  • VTGN is committed to developing and commercializing PH94B, a first-in-class pherine nasal spray with potential to go beyond the current standard of care for acute treatment of social anxiety disorder and other anxiety-related disorders

Anxiety induced by the COVID-19 pandemic during the last year has been linked with surging use of benzodiazepines or “benzos,” a drug class commonly prescribed to treat anxiety and other disorders – a trend with potential to create a new wave of misuse, overuse and addiction among users while leaving physicians concerned about long-term detrimental side effects (https://ibn.fm/FFhjW). As a proactive response to what many critics are calling a “benzo epidemic” (https://ibn.fm/777mk), VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company headquartered in South San Francisco, is currently committed to developing a new generation of medicines that go beyond the current standard of care for anxiety, depression, and other central nervous system (“CNS”) disorders. VistaGen’s CNS pipeline includes multiple innovative drug candidates for treatment of anxiety and depression disorders, each of which has demonstrated favorable safety results in all clinical studies to date and significant commercialization potential in multiple neuropsychiatric markets.

Anxiety is on the rise, according to a recent poll by the American Psychiatric Association, revealing that up to 62% of respondents have serious concerns about the effects of COVID-19 on themselves or loved ones. Additionally, prescriptions for benzodiazepines spiked 34% during the early stages of the pandemic according to a study of over three million people, suggesting a link between the rise of anxiety and increased coverage of the COVID-19 issue in the media.

The use of benzodiazepines to treat anxiety has grown steadily since their discovery in the 1950s. Commonly classified as “minor tranquilizers,” benzodiazepines are prescribed to treat anxiety, panic disorders and seizures by calming nerve impulses and creating a sense of relaxation and well-being. Unfortunately, however fast-acting and highly effective they may be, benzodiazepines are also extremely addictive, earning them a Schedule IV controlled substance classification by the Drug Enforcement Agency (“DEA”) due to their potential for abuse. In September 2020, the FDA’s Drug Safety Communication (“DSC”) noted that there were 92 million prescriptions of benzodiazepines in 2019 and also detailed safety concerns regarding the serious risks of abuse, addiction, physical dependence, and withdrawal reactions linked to long-term use of benzodiazepines. As a result, in the DSC, the FDA announced that it is requiring an updated Boxed Warning, the FDA’s most prominent type of safety warning, for all benzodiazepine medications (https://ibn.fm/08UKT).

According to many medical practitioners, benzodiazepines have serious long-term consequences. Use of the drug has been associated with the development of an increased tolerance that requires higher amounts to achieve the same effect. Additional long-term consequences include addiction, future cognitive problems and incapacitating withdrawal symptoms.

VistaGen is committed to developing therapies that go beyond the limits of the current standard of care. To advance on that goal, VistaGen is currently preparing to launch Phase 3 clinical development of its PH94B for the acute treatment of anxiety in adults with social anxiety disorder (“SAD”), the third most common mental illness among Americans.  PH94B is a first in class pherine nasal spray designed with potential to deliver the rapid-onset anti-anxiety effects of benzodiazepines, but without the side effects and safety concerns associated with their use.  VistaGen currently anticipates launching its U.S. Phase 3 development program for acute treatment of SAD during the second quarter of this year.  The Company is also planning to launch exploratory Phase 2 studies in 2021 focused on several additional anxiety-related disorders, including adjustment disorder, postpartum anxiety, and pre-procedural (pre-MRI) anxiety (https://ibn.fm/bVbBy).

For more information, visit the company’s website at www.VistaGen.com.

NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Monday, February 22nd, 2021 Uncategorized Comments Off on $VTGN Committed to Developing New Generation Alternatives to Current Standard of Care for Anxiety Disorders

$UEC Looks to Continue to Trade Above its Annual-High Share Price Today

Shares of Uranium Energy Corp. (NYSE American:UEC) traded at a new 52-week high today of $2.56. This new high was reached on below average trading volume as 2.5 million shares traded hands, while the average 30-day volume is approximately 5.1 million shares.

Uranium Energy Corp. (NYSE American:UEC) is currently priced 14.3% above its average consensus analyst price target of $2.16.

Uranium Energy Corp is engaged in the uranium mining and related activities, including exploration, pre-extraction, extraction and processing, on uranium projects located in the United States and Paraguay. In South Texas, the company’s hub-and-spoke operations are anchored by the fully licensed Hobson processing facility which is central to the Palangana, Burke Hollow and Goliad ISR projects. In Wyoming, it controls the Reno Creek project, which is the largest permitted, pre-construction ISR uranium project in the U.S. Additionally, the company controls a pipeline of uranium projects in Arizona, New Mexico and Paraguay, a uranium/vanadium project in Colorado and the highest-grade and largest undeveloped Ferro-Titanium deposits in the world, located in Paraguay.

In the past 52 weeks, shares of Uranium Energy Corp. have traded between a low of $0.35 and a high of $2.56 and is now at $2.52, which is 620% above that low price.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Monday, February 22nd, 2021 Uncategorized Comments Off on $UEC Looks to Continue to Trade Above its Annual-High Share Price Today

$TOBAF Announces Record Sales of Flagship Product Since E-Commerce Launch on Feb. 17

TAAT(TM) Lifestyle & Wellness (CSE: TAAT) (OTCQB: TOBAF) (FRANKFURT: 2TP2), a life sciences company dedicated to giving legal-aged smokers the choice to keep the smoking experience that they enjoy with no nicotine and no tobacco, reported more than C$50,000 sales from its online site in the first two days of being live; that number had grown to more than C$100,000 by the end of the weekend. Orders placed through the site, which was launched on Wednesday, Feb. 17, at 9 a.m. ET, were shipped to more than 20 different U.S. states. The site offers cartons of TAAT(TM) Original, Smooth and Menthol for purchase as well as a Taste Explorer Bundle consisting of one 20-stick pack of each of the three TAAT varieties. The announcement noted that TAAT has also added new retail points of sale throughout the state of Ohio, where the company launched retail sales of its product in December 2020. “To sell more than C$100,000 worth of a relatively new product in such a short period is absolutely exceptional,” said TAAT CEO Setti Coscarella in the press release. “Countless smokers aged 21+ in the United States have been eagerly awaiting the launch of our online store on Wednesday, which I believe has contributed significantly to our product sales this past week. Our iterative rollout of TAAT in the United States has been very strategically planned to test the initial reactions of smokers aged 21+ when introduced to the concept of a nicotine-free and tobacco-free smoking experience, while also gauging reception of the product after it is sampled for the first time. Over the past two months, we have had the opportunity to gather quite a bit of feedback about TAAT from smokers aged 21+ as well as retailers and wholesalers of tobacco. I believe those insights have proven useful, as they played a role in creating our strategies for launching the TAAT online store on Wednesday, which has been a remarkable success so far.”

To view the full press releases, visit http://ibn.fm/IuAji and http://ibn.fm/ajFYu

About TAAT Lifestyle & Wellness Ltd.

TAAT Lifestyle and Wellness has developed TAAT,  which is a tobacco-free and nicotine-free alternative to traditional cigarettes offered in Original, Smooth and Menthol varieties. TAAT’s base material is Beyond Tobacco(TM), a proprietary blend that undergoes a patent-pending refinement technique causing its scent and taste to resemble tobacco. Under executive leadership with Big Tobacco pedigree, TAAT was launched first in the United States in Q4 2020 as the company seeks to position itself in the $814 billion global tobacco industry. For more information, please visit www.TAATGlobal.com.

NOTE TO INVESTORS: The latest news and updates relating to TOBAF are available in the company’s newsroom at http://ibn.fm/TOBAF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Monday, February 22nd, 2021 Uncategorized Comments Off on $TOBAF Announces Record Sales of Flagship Product Since E-Commerce Launch on Feb. 17

$PCSA Featured in Research Report

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, was featured in a research report by Encode Ideas L.P., a health care focused research firm. The full research publication is available at https://ibn.fm/NqQs7. The report reads, “Processa’s pipeline is constructed of development-stage assets that have substantial legacy human data, where the company believes a new approach (dosing, indication, trial design, etc.) can unlock latent value. Processa’s management (David Young, Questcor) and board (Khalid Islam, Gentium and Fennec) have a history of successful drug reclamation projects. The company’s lead asset, eniluracil or PCS6422, was a GSK drug that has been studied in over 1,500 cancer patients, where Processa believes slight changes to the dosing regimen and study design can address previous shortcomings. The other pipeline product of note, PCS499, comes from Concert Pharmaceuticals, where it was studied in Ph2 for diabetic nephropathy, but Processa believes it is better suited for a rare dermatology indication, Necrobiosis Lipoidica (‘NL’). We are enthusiastic about both assets, in particular PCS6422, and feel if there is latent value in either or both, this is the team that can unearth it.”

To view the full press release, visit: https://ibn.fm/xBlGX

About Processa Pharmaceuticals Inc.

The mission of Processa is to develop products with existing clinical evidence of efficacy for patients with unmet or underserved medical conditions who need treatment options that improve survival and/or quality of life. The company used these criteria for selection to further develop its pipeline programs to achieve high-value milestones effectively and efficiently. Active pipeline programs include: PCS6422 (metastatic colorectal cancer and breast cancer), PCS499 (ulcerative necrobiosis lipoidica) and PCS12852 (GI motility/gastroparesis). The members of the Processa development team have been involved with more than 30 drug approvals by the FDA (including drug products targeted to orphan disease conditions) and more than 100 FDA meetings throughout their careers. For more information, visit the company’s website at www.ProcessaPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to PCSA are available in the company’s newsroom at http://ibn.fm/PCSA

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Monday, February 22nd, 2021 Uncategorized Comments Off on $PCSA Featured in Research Report

$WRAP Sets Fourth Quarter and Full Year 2020 Conference Webcast for Thursday, March 4, 2021 at 4:30 p.m. ET

TEMPE, Ariz., Feb. 18, 2021 — Wrap Technologies, Inc. (the “Company” or “WRAP”) (Nasdaq: WRAP ), an innovator of modern policing solutions, will hold a Zoom video webcast on Thursday, March 4, 2021 at 4:30 p.m. Eastern time to discuss its financial and operational results for the fourth quarter and full year ended December 31, 2020. Financial and operational results will be issued in a press release prior to the webcast.

WRAP management will host the presentation, followed by a question and answer period. To RSVP for the event in advance, please click here .

Date: Thursday, March 4, 2021
Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time)
RSVP: Webcast Registration Link

Please join the webinar 5-10 minutes prior to the start time. An archived replay will be available after the presentation ends via the investor relations section of the company’s website .

About WRAP
WRAP Technologies, Inc. is an innovator of modern policing solutions. The Company’s BolaWrap 100 product is a patented, hand-held remote restraint device that discharges an eight-foot bola style Kevlar® tether to restrain an individual at a distance from 10 to 25 feet. Developed by award winning inventor Elwood Norris, the Company’s Chief Technology Officer, the small but powerful BolaWrap 100 assists law enforcement in safely and effectively deescalating encounters, especially those involving an individual in crisis. BolaWrap 100 has already been used to safely apprehend suspects without injury in a number of cities including Los Angeles, Sacramento, Fresno, Bell, Albuquerque, Minneapolis, West Palm Beach, Fort Worth, and Oak Ridge. For information on the Company, please visit www.wrap.com.

Follow WRAP here:

WRAP on Facebook: https://www.facebook.com/wraptechnologies/
WRAP on Twitter: https://twitter.com/wraptechinc
WRAP on LinkedIn: https://www.linkedin.com/company/wraptechnologies/

Trademark Information
BolaWrap and Wrap are trademarks of WRAP Technologies, Inc. All other trade names used herein are either trademarks or registered trademarks of the respective holders.

WRAP Contact:

Paul M. Manley
VP – Investor Relations
(612) 834-1804
pmanley@wrap.com

Thursday, February 18th, 2021 Uncategorized Comments Off on $WRAP Sets Fourth Quarter and Full Year 2020 Conference Webcast for Thursday, March 4, 2021 at 4:30 p.m. ET

$VTGN Committed to Developing New Generation of Medicines with Potential to Treat Rising Mental Health Challenges from Depression

  • Mental health experts note growing concern over impact of COVID-19 on nation’s mental health
  • Compounding stress could have serious health, social consequences
  • VTGN offers new hope to those dealing with depression disorders

A new survey from the American Psychological Association (“APA”) shines a spotlight on the growing concern about the impact of the global pandemic on the nation’s mental health (https://ibn.fm/ukaIx). These rising numbers, as well as the treatment for mental health illness and disorders, is of great concern to VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medications that goes beyond the standard of care for anxiety and depression.

Nearly eight in ten adults (78%) report that the coronavirus pandemic is a significant source of stress in their lives, while three in five (60%) say the number of issues America faces is overwhelming to them, according to the “Stress in America(TM) 2020: A National Mental Health Crisis” survey conducted by the Harris Poll on behalf of APA. The survey goes on to note this sobering statistic: Nearly one in five adults (19%) say their mental health is worse than it was at this time last year.

APA CEO Arthur C. Evans Jr. noted that “this survey confirms what many mental health experts have been saying since the start of the pandemic: Our mental health is suffering from the compounding stressors in our lives. This compounding stress will have serious health and social consequences if we don’t act now to reduce it. We’re already seeing this with some of the youngest members of our nation, who just seven months into this crisis are beginning to show signs of serious mental health issues, such as depression and anxiety.”

Depression and anxiety are at the forefront of concern for VistaGen, a company working to develop innovative product candidates to address these substantial issues (https://ibn.fm/vLnl9).  For example, FDA-approved oral antidepressants are slow to act and are associated with significant potential side effects such as anxiety, nausea and vomiting, somnolence and sexual dysfunction.  VistaGen’s PH10 is an innovative pherine nasal spray designed to have rapid-onset therapeutic potential in several neuropsychiatric indications involving depression. Following completion of successful exploratory Phase 2A clinical development, the Company is preparing to launch a planned Phase 2B clinical study of PH10 in major depressive disorder in early 2022. With its rapid-onset pharmacology, potential lack of systemic exposure and favorable safety results observed in all clinical studies to date, PH10 has potential to go beyond the current standard of care for depression as a novel stand-alone treatment for multiple depression disorders.

For more information, visit the company’s website at www.VistaGen.com.

NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Thursday, February 18th, 2021 Uncategorized Comments Off on $VTGN Committed to Developing New Generation of Medicines with Potential to Treat Rising Mental Health Challenges from Depression

$SRAX Sees Sequire’s User Numbers Swell to 3 Million Retail Investors

  • SRAX’s Sequire has announced that 3 million retail investors are now using its investor intelligence platform
  • Sequire’s growth had been predicated on its broad product offering, provision of digital investor–relations tools
  • Sequire recently purchased LD Micro, a small and micro-cap company focused platform, to further bolster corporate presence

SRAX (NASDAQ:SRAX), a digital marketing pioneer focused on providing consumer data management services, recently revealed that Sequire, its investor intelligence SaaS platform, had grown to having over 3 million retail investors on its platform (https://ibn.fm/AzKzM). Launched as a stand-alone platform in early 2020, Sequire has seen its growth accelerate at an astounding rate – with the mix of investors and traders currently using its platform rising from 1 million to 3 million in a matter of mere months. The company has also attracted over 91 publicly-listed companies as subscribers on its platform (https://ibn.fm/5ZKtk) – an explosion of growth largely driven by Sequire’s extensive range of services.

Sequire’s popularity has largely predicated on the breadth of its platform and the unique suite of products available to the company’s corporate subscribers. With companies increasingly looking to adopt digital technology and the data generated from such mediums as a way of improving their engagement with investors and stakeholders alike, Sequire has sought to bridge the gap between publicly-listed corporations and…

Read more »

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Thursday, February 18th, 2021 Uncategorized Comments Off on $SRAX Sees Sequire’s User Numbers Swell to 3 Million Retail Investors

$POAI Announces $17.6M Private Placement

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced its entry into securities purchase agreements with certain institutional and accredited investors to raise approximately $17.6 million through the issuance of an aggregate of 9,043,766 shares of its common stock and warrants to purchase up to an aggregate of 4,521,883 shares of common stock, at a purchase price of $1.95 per share of common stock and associated warrant. The private placement is priced at-the-market under Nasdaq rules. Subject to the satisfaction of customary conditions, the closing of the private placement is expected to occur on or about Feb. 22, 2021. H.C. Wainwright & Co., LLC acted as the exclusive placement agent for the offering. Predictive Oncology intends to use up to approximately $5.88 million of the net proceeds to repay certain indebtedness and the remaining net proceeds for general corporate purposes.

To view the full press release, visit: https://ibn.fm/9Rw9l

About Predictive Oncology Inc.

Predictive Oncology operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins, and protein complexes. For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Thursday, February 18th, 2021 Uncategorized Comments Off on $POAI Announces $17.6M Private Placement

$MGROF Research Discovers Wearable Devices Can Detect the Coronavirus

Results from various studies conducted by leading research institutions in the Unites States have found that wearables such as smartwatches, which measure an individual’s heart rate, also possess the ability to identify whether a person is coronavirus positive — even before symptoms start showing or the virus is detected using a test.

These results, which were announced from institutions including Stanford University, California and New York’s Mount Sinai Health System, demonstrate that these devices detect the virus’s presence by measuring the pulse of a person’s heartbeat and their skin temperature as well as other biometric and physiological features.

Some of the devices mentioned in the report include Fitbit and Garmin watches and the Apple Watch. Experts state that the technology these devices use may be useful in the future to help decrease the spread of both the pandemic as well as other transmissible diseases.

A few members of the research team stated that their objective was to utilize the technology available to discover how fast the coronavirus or any other infection could be identified even before laboratory tests were conducted or symptoms begun showing.

Icahn School of Medicine assistant professor Rob Hirten explained that the goal of the study was to detect infections before individuals discovered they were sick or even identify the time an individual became infected. He further explains that the researchers were aware of the inflammatory effect the coronavirus had on the human body, adding that the variability markers of an individual’s heart rate changed as inflammation advanced in the body. This knowledge, he said, could help researchers predict when individuals were infected with a disease.

The researchers stated that to conduct the study, they observed 300 health-care personnel from Mount Sinai who wore Apple Watches over a five-month period, between April 29 and September 29, 2020.

The researchers also quoted a report conducted by the Centers for Disease Control in the U.S., which explained that a considerable amount of transmission takes place by carriers who were asymptomatic. They then noted that their findings would be useful in effectively containing the spread of the coronavirus.

The researchers’ interview, which was conducted by CBS, also highlighted a separate study that demonstrated the difference in the rates of heartbeats of some COVID-19 patients before the disease’s symptoms began showing.  Additionally, alarm systems were developed for the wearable devices, which would notify a wearer about their heartbeat rates while also ensuring they kept a distance from individuals who had shown any signs of infection.

In most cases, the body may have a fighting chance against different diseases if matters of nutrition are accorded the attention they deserve. Nutrition and nutrients are a top priority for MustGrow Biologics Corp. (CSE: MGRO) (OTCQX: MGROF) (FRA: 0C0), a company that focuses on developing natural crop protection remedies that can reduce or eliminate the use of synthetic chemicals during cultivation.

NOTE TO INVESTORS: The latest news and updates relating to MustGrow Biologics Corp. (CSE: MGRO) (OTCQX: MGROF) (FRA: 0C0) are available in the company’s newsroom at https://ibn.fm/MGROF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Thursday, February 18th, 2021 Uncategorized Comments Off on $MGROF Research Discovers Wearable Devices Can Detect the Coronavirus

$CLXPF Massachusetts General Hospital to Study How Psychedelics Influence the Brain

Massachusetts General Hospital is partnering with Atai Life Sciences to study the effects of psychedelics on the human brain.

Atai Life Sciences is a biotech firm focused on developing medications to manage schizophrenia while also working on creating alternative treatments for various mental health conditions such as anxiety and depression.

The two organizations decided to work together after the hospital set up a program, named the Center for Neuroscience of Psychedelics, to study psychedelic therapy. A psychiatric at the hospital, Jerrold Rosenbaum is the head of the program and has specialized in the treatment of psychiatric disorders. Rosenbaum stated that there was a need to better comprehend the effects that psychedelics had on the human brain.

Rosenbaum revealed that he became interested in the psychedelic therapy field after a friend began studying the subject, which prompted Rosenbaum to reevaluate his perceptions on psychedelic substances. His friend is now serving as the director of the Center for Neuroscience of Psychedelics advisory council.

Rosenbaum explained that in the beginning he perceived hallucinogens as recreational drugs that had been banned from being studied for many years. However, as he begun to learn more about the substances, he realized that psychedelics presented an opportunity that had yet to be developed.

The Center for Neuroscience of Psychedelics is currently focused on neuroplasticity, which refers to the ability of the cells in the brain to alter themselves. Recent research has demonstrated that psychedelics enhance this activity in the brain, which may change how depression influences the brain.

Atai’s chief scientific officer Srinivas Rao explained that psychedelic therapy would help boost the effects of psychedelic substances by making use of the neuroplastic state.  Atai and Massachusetts General are not revealing the particular substances that will be tested in the lab or on animals; neither are they disclosing the financial terms of their partnerships. However, Stephen Haggarty, who is the hospital’s researcher co-leading the collaboration, stated that it would involve psychedelics that were not similar to psilocybin, describing them as the next generation of psychedelics. Additionally, Haggarty stated that the molecule showed a lot of potential based on reports of the molecule in human beings.

Earlier in November, Atai Life Sciences had announced that it had raised more than $125 million in financing, which would be used to support the testing and development of psychiatric treatments. This brought the company’s total funding to roughly $250 million.

Atai Life Sciences was established in 2018 by Compass Pathways as a way for the organization to raise funds.

Atai isn’t the only company looking to develop psychedelic medicines. Cybin Inc. (NEO: CYBN) (OTC: CLXPF) is also intent on developing psychedelic medicines, especially given the encouraging preliminary research results showing the potential of these substances in treating mental illnesses.

NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (OTC: CLXPF) are available in the company’s newsroom at https://ibn.fm/CYBN

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Thursday, February 18th, 2021 Uncategorized Comments Off on $CLXPF Massachusetts General Hospital to Study How Psychedelics Influence the Brain

$CNSP Announces Key Milestone, Progress Toward Collaborative Clinical Trials

CNS Pharmaceuticals (NASDAQ: CNSP) and WPD Pharmaceuticals (CSE: WBIO) (8SV1.F) (“WPD”), biopharmaceutical companies specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that WPD received a positive opinion of the Lower Silesian Medical Chamber Ethics Committee in Wroc¿aw, Poland for its planned upcoming Berubicin clinical trial in adults with Glioblastoma Multiforme (“GBM”) under the WPD-201 Clinical Trial Protocol. CNS Pharmaceuticals has received study level approval from the Central IRB for the CNS-201 Clinical Trial Protocol. Berubicin is the company’s novel anthracycline candidate for the treatment of a number of serious oncology indications, currently in development for the treatment of GBM. CNS entered into a sublicense agreement with WPD in November 2019, which provided WPD the commercial rights to Berubicin in select territories in Europe and Asia. “We are pleased for WPD to achieve this key milestone and are encouraged by their continued execution in furthering the development of Berubicin,” said John Climaco, CEO of CNS Pharmaceuticals. “Importantly, we believe WPD’s Ethics Committee approval of the WPD-201 Clinical Trial Protocol coupled with our recent IND approval and Central IRB Study Level approval, position us one step closer to collaboratively initiating three clinical trials for Berubicin during 2021. We look forward to continuing our trial preparations, as well as WPD’s planned submissions to the Polish Competent Authority.”

To view the full press release, visit: https://ibn.fm/qNRoS

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase 1 clinical trial with Berubicin in malignant brain tumors, which Reata conducted in 2006. In this trial the overall response rate of stable disease or better was 44%. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of Feb. 20, 2020. These Phase 1 results represent a limited patient sample size and, while promising, are not a guarantee that similar results will be achieved in subsequent trials. By the end of the first quarter of 2021, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the U.S., while a sub-licensee partner undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial in pediatric GBM patients in Poland. Its second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies that it is 500 times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation. For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at http://ibn.fm/CNSP

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Thursday, February 18th, 2021 Uncategorized Comments Off on $CNSP Announces Key Milestone, Progress Toward Collaborative Clinical Trials

$MOTNF Australian Feds Rule Out Private EV Purchase Subsidies

Electric vehicles (“EVs”) are still too expensive for the average buyer. Although EVs are poised to ultimately replace internal combustion vehicles as countries around the world strive to reduce carbon emissions, improve air quality and achieve climate goals, the initial purchase costs put them out of the reach of most households. To make them more affordable and boost EV adoption, authorities in several countries have been offering subsidies, incentives and tax credits for certain electric vehicle purchases.

Australia, however, has chosen to go a different route after the federal government recently announced that it was ruling out subsidies for private EV purchases. According to the 40-page Future Fuels Strategy, published last week, the government may subsidize businesses that replace their fleets with electric vehicles. The publication outlines the Australian Federal Government’s automotive policy platform, stating that it will focus on three issues: enabling consumer choice, stimulating industry development and reducing emissions in the road transportation sector.

The strategy report states that rather than privately owned EVs, fleets are the more effective path for pushing the adoption of new vehicle technology. By incentivizing fleets, the publication states, Australians can become familiarized with “new technologies.” For instance, the publication states, most Australians had their first experience with a hybrid vehicle via a taxi or company vehicle. Once consumers became aware of these vehicles and their benefits, private purchasers began buying them in droves.

Additionally, subsidizing fleet purchases would also help to stimulate the fledgling second-hand EV market. On average, businesses tend to replace their vehicles more frequently than private buyers, and by making EVs more affordable for fleets, the federal government will inevitably be beefing up the supply of second-hand electric vehicles at lower prices, the publication states.

Using taxpayer-funded subsidies to boost EV adoption by private buyers would be inefficient and “an inefficient way to reduce emissions,” the report continues. It adds that the primary focus will instead be on promoting the adoption of commercial EV fleets; expanding the current charging infrastructure; increasing battery integration; supporting the manufacturing side of things;and improving public education about EVs, climate change and clean, renewable energy.

Tony Weber, chief executive of the Federal Chamber of Automotive Industries (“FCAI”), calls the 40-page report a “step in the right direction.” The report also has the support of the Australian Automobile Association, the peak body for motoring clubs such as the NRMA and RACV, which represent more than 7 million motorists.

On the other hand, the chief executive of Australia’s Electric Vehicle Council says the proposal is disappointing, especially as every other major country subsidizes electric vehicles.

Meanwhile in North America, Clean Power Capital Corp. (CSE: MOVE) (FWB: 2K6A) (OTC: MOTNF) has opted to specialize in identifying and then financing companies within the renewable energy sector, such as hydrogen fuel cells.

NOTE TO INVESTORS: The latest news and updates relating to Clean Power Capital Corp. (CSE: MOVE) (FWB: 2K6A) (OTC: MOTNF) are available in the company’s newsroom at https://ibn.fm/MOTNF

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com

Green Car Stocks is part of the InvestorBrandNetwork.

Thursday, February 18th, 2021 Uncategorized Comments Off on $MOTNF Australian Feds Rule Out Private EV Purchase Subsidies

$BHAT Enters Strategic Agreement to Provide Augmented Reality Immersive Classes

Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT), a leading producer, developer and operator of augmented reality (“AR”) interactive entertainment games, toys and educational materials in China, today announced its entry into a three-year agreement with Zhong Ya (Shenzhen) International Education Investment Co. Ltd. (“Zhong Ya”). Under the agreement, Blue Hat will provide its Augmented Reality Immersive Classes (“ARIC”) to Zhong Ya’s 680 kindergartens located in Guangdong Province. Blue Hat will also develop for Zhong Ya an overall kindergarten curriculum and technology platform with a focus on STEAM (Science, Technology, Engineering, Art and Mathematics), taking into account social and emotional, communication and language, as well as physical development. “We are pleased to begin this partnership with Zhong Ya and look forward to working closely with them on integrating our digital solutions with a new STEAM-focused curriculum for their young students,” said Xiaodong Chen, CEO of Blue Hat. “We are excited to share our innovative education tools with Zhong Ya teachers as the success of the new platform and curriculum largely hinge upon properly training teachers in using these resources when educating students. We believe this partnership is yet another testament to the effectiveness of our interactive educational technology and we have begun the rollout of Blue Hat’s ARIC to these 680 kindergartens since the beginning of 2021. As a result of this rollout, we expect to see a substantial increase in our revenues from interactive education in 2021.”

To view the full press release, visit http://ibn.fm/i6rLk

About Blue Hat

Blue Hat Interactive Entertainment Technology is a producer, developer and operator of AR interactive entertainment games and toys in China, including interactive educational materials, mobile games and toys with mobile-game features. The company’s entertainment platform creates unique user experiences by connecting physical items to mobile devices, which creates a rich visual and interactive environment for users through the integration of real objects and virtual scenery. Distinguished by its own proprietary technology, Blue Hat aims to create an engaging, interactive and immersive community for its users. For more information, please visit the company’s investor relations website at www.IR.BlueHatGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to BHAT are available in the company’s newsroom at http://ibn.fm/BHAT

About ChineseWire

ChineseWire (CW) is a specialized communications platform focused on promising China-based companies that are listed in North America. As one of 40+ brands within the InvestorBrandNetwork (“IBN”), CW provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution to IBN’s millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, CW is uniquely positioned to best serve private and public Chinese companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CW brings its clients unparalleled visibility, recognition and brand awareness. CW is where news, content and information converge.

For more information, please visit https://www.ChineseWire.com

Please see full terms of use and disclaimers on the ChineseWire website applicable to all content provided by CW, wherever published or re-published: https://www.ChineseWire.com/Disclaimer

ChineseWire
Los Angeles, California
www.ChineseWire.com
310.299.1717 Office
Editor@ChineseWire.com

ChineseWire is part of the InvestorBrandNetwork.

Thursday, February 18th, 2021 Uncategorized Comments Off on $BHAT Enters Strategic Agreement to Provide Augmented Reality Immersive Classes

$AMST Offers Tech, Online Learning That Brings Businesses, Schools, Universities into Digital Age

Amesite(NASDAQ: AMST), an artificial intelligence (“AI”) software company providing the most advanced AI-powered online learning ecosystems for business, higher education and K-12, is featured in an AudioPressRelease broadcast. Titled “Essential E-Learning Ecosystems Move to the Head of the Class,” the broadcast notes that to achieve education transformation, technology must be able to easily address both new and legacy programs. The broadcast, which focuses on Amesite’s unique and powerful online learning services, observes that the days of one-size-fits-all video cassette sessions and printed educational material are long gone. “People simply don’t learn, retain or have the opportunity to excel under those moribund modalities,” the broadcast reports. “Furthermore, there’s a necessity today to be able to teach a multiplicity of individual complexities such as safety and compliance Issues or new skills in data management delivered digitally and customizable in a single ecosystem with the ability to track and enhance efficacy.”

To hear the full broadcast, visit https://ibn.fm/34tcA

To view the full press release, visit http://ibn.fm/dYRbv

About Amesite Inc.

Amesite is a high-tech, artificial intelligence software company offering a cloud-based platform and content creation services for business, university and K-12 learning and upskilling. Amesite-offered courses and programs are branded to its customers. For more information about the company, please visit www.Amesite.com.

NOTE TO INVESTORS: The latest news and updates relating to AMST are available in the company’s newsroom at http://ibn.fm/AMST

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Thursday, February 18th, 2021 Uncategorized Comments Off on $AMST Offers Tech, Online Learning That Brings Businesses, Schools, Universities into Digital Age

$TOBAF Announces Opening of Online Store

TAAT(TM) (CSE: TAAT) (OTCQB: TOBAF) (FRANKFURT: 2TP2) today announced the opening of its online store where consumers in the U.S. can buy the company’s tobacco-free and nicotine-free alternative to traditional cigarettes. The update reads, “Residents of the United States will now be able to purchase TAAT(TM) online!  Cartons of TAAT(TM) Original, Smooth, and Menthol can be ordered to addresses in most U.S. states. It’s time for smokers aged 21+ to order TAAT(TM) and make the better choice!”

To view the full press release, visit https://ibn.fm/A6lmC

About TAAT(TM) Lifestyle & Wellness Ltd.

The company has developed TAAT(TM), which is a tobacco-free and nicotine-free alternative to traditional cigarettes offered in “Original,” “Smooth” and “Menthol” varieties. TAAT(TM)’s base material is Beyond Tobacco(TM), a proprietary blend that undergoes a patent-pending refinement technique causing its scent and taste to resemble tobacco. Under executive leadership with “Big Tobacco” pedigree, TAAT(TM) was launched first in the United States in Q4 2020 as the company seeks to position itself in the $814 billion* global tobacco industry. For more information, please visit www.TAATGlobal.com.

*British American Tobacco – The Global Market

NOTE TO INVESTORS: The latest news and updates relating to TOBAF are available in the company’s newsroom at http://ibn.fm/TOBAF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Wednesday, February 17th, 2021 Uncategorized Comments Off on $TOBAF Announces Opening of Online Store

$XPHYF How Past Stigma and Recreational Use Are Slowing Psychedelic Science

According to recent research conducted in America that involved 952 individuals, psychedelic researchers who admitted to using psychedelic substances are often viewed by their abstinent counterparts as having less integrity. The study, which was reported in the “Public Understanding of Science” journal, proposes that stereotypes about both psychedelics and the individuals who use them may affect an individual’s view of researchers.

University of Zurich’s Matthias Forstmann, who is the one of the authors of the study, stated that the personal use of these substances by the scientists studying them was a common occurrence, although very few researchers were open about it. He went on to explain that many researchers publicize their association with the psychedelics field, despite knowing next to nothing about how such public associations and admissions impact the public’s view of the research being conducted by these scientists.

In the first two studies, participants read a short story about a researcher who was carrying out research on psychedelic substances. The scientists discovered that after the story disclosed that the researcher had comprehensive personal experience with ingesting psychedelics, the participants perceived the researcher as possessing less scientific integrity, in comparison with when the story mentioned that the researcher had no personal experience with the psychedelic substances.

During the third study, participants were required to assess the quality of research that was being presented at a conference on the “science of psychedelics.” The participants described the conference as either comprising of normal social activities, such as a local brewery tour, or including social activities that were related to psychedelics, such as a group meditation session.

Along with assessing the research quality, participants were also shown pictures of both versions of the conference, with pictures of the former version of the conference showing it took place in a typical university auditorium and the latter in a spacious hall that had colorful light installations.

Researchers found that the participants perceived the research quality at the conference to be lower when it was inclusive of psychedelic imagery and activities. The study’s findings indicate that being linked to the psychedelic subculture or admitting to the personal use of psychedelics could negatively influence the public’s view of a researcher’s work with regard to the validity of that work as well as the integrity of the researcher.

Study authors Christina Sagioglou and Matthias Forstmann noted that additional research was required to learn more about the processes that made up the basis for the effects they observed in the study.

Those perceptions notwithstanding, many companies are pressing ahead with R&D in the psychedelics sector. An example is XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), which has invested its bioscience acceleration efforts on developing psychedelic medicines.

NOTE TO INVESTORS: The latest news and updates relating to XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) are available in the company’s newsroom at https://ibn.fm/XPHYF

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Wednesday, February 17th, 2021 Uncategorized Comments Off on $XPHYF How Past Stigma and Recreational Use Are Slowing Psychedelic Science

$WTER Releases Financial Report, Posts Record Q3 2021 Revenue

The Alkaline Water Company (NASDAQ: WTER) (CSE: WTER), a producer of premium bottled alkaline water, flavor-infused waters and CBD-infused products, announced that revenue for Q3 2021 reached $10.2 million an increase of $1.7 million year over year and a record for the company. The company also noted that earnings per share for Q3 2021, the period ending Dec. 31, 2020, were up 14.3% compared to the previous year and that the company’s Direct Store Delivery (“DSD”) had reached more than 10,000 customers, with its A888CBD(TM) line seeing its national distribution network increasing with KeHE, UNFI, BettermentRS and broker C.A. Fortune. The company also announced that it held a live call to discuss Q3 2021 earnings on Feb. 16, 2021. “We are proud to announce that we delivered record fiscal third quarter revenue of $10.2 million,” said The Alkaline Water Company president and CEO Ricky Wright in the press release. “Our E-Commerce, A88CBD, single-serve offerings, eco-friendly aluminum bottles, and flavor-infused waters all contributed toward the record. Each business line continues to grow, and we expect a significant contribution from them over the next 12 months. We are excited that the momentum we gained over the summer in our flagship brand Alkaline88 continues. Based on 13 week Nielsen scanner data ending 12/26/20, we continue to be the fastest-growing top 10 value-added water in the country. We outperform the category volume growth by almost 2 times and the unit growth by over 5 times. We are now the eighthlargest vendor in the category. We see continued strength in the 1/23/21 Nielsen scanner data as well.”

To view the full press releases, visit http://ibn.fm/WIVjB and http://ibn.fm/zhsnB

About The Alkaline Water Company

Founded in 2012, The Alkaline Water Company is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88(R), is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88(R) delivers perfect 8.8 pH balanced alkaline drinking water with trace minerals and electrolytes and boasts its trademarked label Clean Beverage. Quickly being recognized as a growing lifestyle brand, Alkaline88(R) launched A88 Infused(TM) in 2019 to meet consumer demand for flavor-infused products. A88 Infused(TM) flavored water is available in seven unique all-natural flavors, with new flavors coming soon. Additionally, in 2020, the company launched A88 Infused Beverage Division Inc., which includes the company’s CBD water and flavor-infused water. For the company’s topical and ingestible offerings, A88 Infused Products includes both the company’s lab-tested, full-spectrum hemp salves, balms, lotions, essential oils and bath salts, along with broad-spectrum hemp beverage shots, powder packs, oil tinctures, capsules and gummies. To learn more about the company, please visit www.A88CBD.com and www.TheAlkalineWaterCo.com.

NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://ibn.fm/WTER

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Wednesday, February 17th, 2021 Uncategorized Comments Off on $WTER Releases Financial Report, Posts Record Q3 2021 Revenue

$SRAX Rise to a New 52-Week High

Shares of SRAX (NASDAQ: SRAX) traded today at $7.10, eclipsing its 52-week high. So far today approximately 365,000 shares have been exchanged, as compared to an average 30-day volume of 930,000 shares.

SRAX Inc is a digital marketing and data technology company with tools to reach and reveal valuable audiences with marketing and advertising communication. In addition to business services and technologies, it also operates a direct to consumer platform, BIGToken, which enables consumers to own, manage and sell access to their digital identity and data. The product portfolio of the company includes SRAX Platform, BiGtoken, SRAX Core, SRAX Lux, and others.

SRAX share prices have moved between a 52-week high of $7.10 and a 52-week low of $1.51 and are now trading 317% above that low price at $6.30 per share.

SRAX (:SRAX) is currently priced 7.7% above its average consensus analyst price target of $5.81.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Wednesday, February 17th, 2021 Uncategorized Comments Off on $SRAX Rise to a New 52-Week High

$PCSA Executes Purchase Agreement to Raise $10.2M

Processa Pharmaceuticals Inc. (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, has executed a securities purchase agreement. The agreement is intended to raise gross proceeds of $10.2 million through the sale of 1,321,132 shares. The shares will be sold at $7.75 per share through a private investment in public equity (“PIPE”) financing. In the announcement, the company reported that the financing attracted both institutional and accredited investors, with the private placement closing expected on or about Feb. 23, 2021. “We believe these additional resources position us to further advance our pipeline of drug candidates for those patients who need better treatment options in cancer and gastroparesis as well as patients who have no real FDA approved treatment for Necrobiosis Lipoidica (‘NL’),” said Processa CEO and chairman Dr. David Young in the press release. “We look forward to seeing the results from our interim analyses in the phase 1B PCS6422 study and the Phase 2B PCS499 study in the 2H 2021.”

To view the full press release, visit http://ibn.fm/L5rXa

About Processa Pharmaceuticals Inc.

The mission of Processa is to develop products with existing clinical evidence of efficacy for patients with unmet or underserved medical conditions who need treatment options that improve survival and/or quality of life. The company uses these criteria for selection to further develop its pipeline programs to achieve high-value milestones effectively and efficiently. PCSA’s active clinical pipeline programs include PCS6422 (“PCS6422”) (metastatic colorectal cancer and breast cancer), PCS499 (“PCS499”) (ulcerative Necrobiosis Lipoidica) and PCS12852 (“PCS12852”) (gastroparesis). The markets of each indication are in excess of $1 billion each. The members of the Processa development team have been involved with more than 30 FDA drug approvals, including drug products targeted to orphan disease conditions, and more than 100 FDA meetings throughout their careers. For more information, visit the company’s website at www.ProcessaPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to PCSA are available in the company’s newsroom at http://ibn.fm/PCSA

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Wednesday, February 17th, 2021 Uncategorized Comments Off on $PCSA Executes Purchase Agreement to Raise $10.2M
Top Small Cap Market News